Abstract: The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of ?-linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.

Abstract: The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of ?-linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.

Abstract: The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of ?-linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.

Abstract: The invention pertains to the use of a composition in reducing the number of infections episodes and the occurrence of infections in young children, said composition comprising: (a) long chain polyunsaturated fatty acids, wherein the amount of arachidonic acid is less than 0.06 gram per 100 gram fatty acid; and comprising, per 100 g fatty acids: (i) 0.3-0.6 gram docosahexaenoic acid; (ii) 0.2-0.4 gram eicosapentaenoic acid; and (b) between 1.5 and 2.5 gram indigestible oligosaccharides per 100 kcal, comprising: (i) 1.4-2 gram short-chain galactooligosaccharides; and (ii) 0.1-0.5 gram long-chain fructopolysaccharides.

Abstract: The invention pertains to the use of a composition in reducing the number of infections episodes and the occurrence of infections in young children, said composition comprising: (a) long chain polyunsaturated fatty acids, wherein the amount of arachidonic acid is less than 0.06 gram per 100 gram fatty acid; and comprising, per 100 g fatty acids: (i) 0.3-0.6 gram docosahexaenoic acid; (ii) 0.2-0.4 gram eicosapentaenoic acid; and (b) between 1.5 and 2.5 gram indigestible oligosaccharides per 100 kcal, comprising: (i) 1.4-2 gram short-chain galactooligosaccharides; and (ii) 0.1-0.5 gram long-chain fructopolysaccharides.

Abstract: The invention relates to a nutritional composition comprising colostrum and a fat blend that is particularly suited the treatment of intestinal dysfunction in HIV patients.

Abstract: The present invention relates to a method for preventing obesity later in life by administering a certain nutritional composition to an infant with the age between 0 and 36 months. The composition comprises linoleic acid and alpha-linolenic acid.

Abstract: The present invention concerns high energy formulations for treatment and/or prevention of faltering growth in infants, in particular for promoting catch-up growth in a sick infant.

Abstract: The present invention relates to a nutritional product for HIV patients. More specifically the invention relates to a nutritional composition that provides carefully selected nutritional ingredients including oligosaccharides and cysteine and/or a source of cysteine specifically supporting HIV patients with nutritionally related symptoms. This invention also relates to the manufacture of a nutritional supplement for use in HIV patients.

Abstract: The invention relates to a nutritional composition comprising colostrum and a fat blend that is particularly suited the treatment of intestinal dysfunction in HIV patients.